• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[罗匹尼罗治疗不宁腿综合征继发慢性失眠的疗效:多导睡眠图数据]

[The efficacy of ropinirole in the treatment of chronic insomnia secondary to restless legs syndrome: polysomnography data].

作者信息

Estivill E, de la Fuente V

机构信息

Unidad de Alteraciones del Sueño, Institut Universitari Dexeus, Barcelona, España.

出版信息

Rev Neurol. 1999;29(9):805-7.

PMID:10696651
Abstract

INTRODUCTION

Following the line of our earlier investigations, we made an open pilot study using a polysomnograph to objectively show the efficacy of Ropinirole in the treatment of chronic insomnia secondary to the restless legs syndrome (RLS).

PATIENTS AND METHODS

We did polysomnograph studies on 5 patients with the characteristics of primary RLS, according to the criteria of the International Group for the study of RLS, who had had chronic insomnia for over 5 years. We used Spiegel's questionnaires to show subjective improvement.

RESULTS

The following parameters were significant between the first night (without treatment) and the second night (with 0.25 mg of Ropinirole) and between night 30 without (treatment) and night 31 (with 0.25 mg of Ropinirole). The results were expressed as average values for the 5 patients with their respective standard deviations. Efficiency of sleep: 62.62% +/- 11.31 as compared with 82.82% +/- 8.80, p = 0.010. After 30 days: 64.88% +/- 17.17 against 88.75% +/- 2.09, p = 0.014. Total time asleep: 295' +/- 51.76 against 397.7 +/- 38.50, p = 0.006. After 30 days: 294.6' +/- 87.40 against 391' +/- 22.38, p = 0.025. Number of periodic movements: 91 +/- 33.59 against 30.8 +/- 35.56, p = 0.011. After 30 days: 189.8 +/- 99.79 against 36.2 +/- 21.56, p = 0.013. All patients had subjective improvement in the parameters of Spiegel's test (p = 0.0005).

CONCLUSIONS

The improvement in efficiency of sleep seen on polisomnography, total time slept and reduction in periodic limb movements were statistically significant. The subjective improvement described was also confirmed by Spiegel's questionnaire.

摘要

引言

按照我们早期研究的思路,我们进行了一项开放性试验研究,使用多导睡眠图客观地显示罗匹尼罗治疗继发于不宁腿综合征(RLS)的慢性失眠的疗效。

患者与方法

根据国际不宁腿综合征研究小组的标准,我们对5例具有原发性RLS特征且患有慢性失眠超过5年的患者进行了多导睡眠图研究。我们使用施皮格尔问卷来显示主观改善情况。

结果

在第一晚(未治疗)和第二晚(服用0.25毫克罗匹尼罗)之间以及第30晚(未治疗)和第31晚(服用0.25毫克罗匹尼罗)之间,以下参数具有显著性差异。结果以5例患者各自的标准差的平均值表示。睡眠效率:分别为62.62%±11.31与82.82%±8.80,p = 0.010。30天后:分别为64.88%±17.17与88.75%±2.09,p = 0.014。总睡眠时间:分别为295分钟±51.76与397.7分钟±38.50,p = 0.006。30天后:分别为294.6分钟±87.40与391分钟±22.38,p = 0.025。周期性运动次数:分别为91±33.59与30.8±35.56,p = 0.011。30天后:分别为189.8±99.79与36.2±21.56,p = 0.013。所有患者在施皮格尔测试参数方面均有主观改善(p = 0.0005)。

结论

多导睡眠图显示的睡眠效率改善、总睡眠时间以及周期性肢体运动减少在统计学上具有显著性。施皮格尔问卷也证实了所描述的主观改善情况。

相似文献

1
[The efficacy of ropinirole in the treatment of chronic insomnia secondary to restless legs syndrome: polysomnography data].[罗匹尼罗治疗不宁腿综合征继发慢性失眠的疗效:多导睡眠图数据]
Rev Neurol. 1999;29(9):805-7.
2
Randomized, double-blind, placebo-controlled, short-term trial of ropinirole in restless legs syndrome.罗匹尼罗治疗不宁腿综合征的随机、双盲、安慰剂对照短期试验
Sleep Med. 2005 Mar;6(2):141-7. doi: 10.1016/j.sleep.2004.12.002.
3
A 52-week open-label study of the long-term safety of ropinirole in patients with restless legs syndrome.一项关于罗匹尼罗对不安腿综合征患者长期安全性的52周开放标签研究。
Sleep Med. 2007 Nov;8(7-8):742-52. doi: 10.1016/j.sleep.2006.09.009. Epub 2007 May 18.
4
Ropinirole treatment for restless legs syndrome.罗匹尼罗治疗不宁腿综合征。
Expert Opin Pharmacother. 2008 Mar;9(4):611-23. doi: 10.1517/14656566.9.4.611.
5
Ropinirole is effective in the long-term management of restless legs syndrome: a randomized controlled trial.罗匹尼罗在不安腿综合征的长期管理中有效:一项随机对照试验。
Mov Disord. 2006 Oct;21(10):1627-35. doi: 10.1002/mds.21050.
6
Efficacy and tolerability of ropinirole in patients with restless legs syndrome and a baseline IRLS total score > or = 24 points--data from the ropinirole clinical trial programme.罗匹尼罗治疗不安腿综合征且国际不安腿综合征评定量表(IRLS)总分基线≥24分患者的疗效和耐受性——来自罗匹尼罗临床试验项目的数据
Curr Med Res Opin. 2006 Oct;22(10):1867-77. doi: 10.1185/030079906X132442.
7
An exploratory retrospective evaluation of ropinirole-associated psychotic symptoms in an outpatient population treated for restless legs syndrome or Parkinson's disease.对接受不安腿综合征或帕金森病治疗的门诊患者中与罗匹尼罗相关的精神症状进行的探索性回顾性评估。
Ann Pharmacother. 2009 Sep;43(9):1426-32. doi: 10.1345/aph.1M183. Epub 2009 Aug 18.
8
Clinical efficacy of ropinirole for restless legs syndrome is not affected by age at symptom onset.罗匹尼罗治疗不宁腿综合征的临床疗效不受症状起始年龄的影响。
Sleep Med. 2008 Dec;9(8):899-902. doi: 10.1016/j.sleep.2007.08.017. Epub 2007 Nov 19.
9
Efficacy and safety of pramipexole in Japanese patients with primary restless legs syndrome: A polysomnographic randomized, double-blind, placebo-controlled study.普拉克索治疗日本原发性不安腿综合征患者的疗效和安全性:一项多导睡眠图随机、双盲、安慰剂对照研究。
Sleep Med. 2010 Jan;11(1):11-6. doi: 10.1016/j.sleep.2009.03.009. Epub 2009 Dec 4.
10
First night efficacy of pramipexole in restless legs syndrome and periodic leg movements.普拉克索治疗不宁腿综合征和周期性腿部运动的首夜疗效。
Sleep Med. 2007 Aug;8(5):491-7. doi: 10.1016/j.sleep.2006.10.008. Epub 2007 May 18.

引用本文的文献

1
A double-blind, randomized, controlled trial to compare the efficacy and tolerability of fixed doses of ropinirole, bupropion, and iron in treatment of restless legs syndrome (Willis-Ekbom disease).一项双盲、随机、对照试验,比较固定剂量的罗匹尼罗、安非他酮和铁剂治疗不安腿综合征( Willis-Ekbom病)的疗效和耐受性。
Ann Indian Acad Neurol. 2016 Oct-Dec;19(4):472-477. doi: 10.4103/0972-2327.194424.
2
Ropinirole for the treatment of restless legs syndrome.罗匹尼罗治疗不宁腿综合征。
Neuropsychiatr Dis Treat. 2006 Dec;2(4):407-19. doi: 10.2147/nedt.2006.2.4.407.
3
Restless legs syndrome: pathophysiology, diagnosis and treatment.
不宁腿综合征:病理生理学、诊断与治疗
CNS Drugs. 2008;22(6):497-518. doi: 10.2165/00023210-200822060-00004.
4
Ropinirole: for the treatment of restless legs syndrome.罗匹尼罗:用于治疗不宁腿综合征。
CNS Drugs. 2004;18(11):747-54; discussion 755-6. doi: 10.2165/00023210-200418110-00004.